Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Tannir, N. M.; Frontera, O. A.; Hammers, H. J.; Carducci, M. A.; McDermott, D. F.; Salman, P.; Escudier, B.; Beuselinck, B.; Amin, A.; Porta, C.; George, S.; Bracarda, S.; Tykodi, S. S.; Powles, T.; Rini, B. I.; Tomita, Y.; McHenry, M. B.; Mekan, S. F.; Motzer, R. J. |
| Abstract Title: | Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2019 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2019 Feb 14-16 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-03-01 |
| Language: | English |
| ACCESSION: | WOS:000489108800548 |
| DOI: | 10.1200/JCO.2019.37.7_suppl.547 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 547 -- Source: Wos |
